Facebook
Twitter
LinkedIn
ForwardOvercoming Obesity 2023 (Live) -Pharmacotherapy for Medically Complicated Obesity: A Case-Based Approach
Demand for pharmacotherapy has increased considerably with the introduction of newer anti-obesity medications (AOM’s). This case-based session will present a variety of clinical scenarios demonstrating the application of pharmacotherapy in obesity complicated by coexistent health conditions such as DM, HTN, chronic kidney disease, atrial fibrillation, hearth failure, psychiatric disease, and eating disorders. Discussion will include managing comorbidities, applying recent clinical trials, and incorporating guideline recommendations in specific cases. The session will also address identifying weight promoting medications and utilizing alternative agents to improve obesity care.
CME/CE Expiration Date: 11/28/23
*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
Learning Objectives
- Evaluate anti-obesity medication (AOM) options in the setting of common chronic diseases
- Apply clinical trials and clinical practice guidelines to patient-centered AOM selection
- Recognize iatrogenic weight gain agents and apply appropriate alternatives
Silvana Pannain, MD
Alpana Shukla, MD, MRCP(UK), FTOS
This session is approved by the American Association of Nurse Practitioners® for 1.25 pharmacology contact hour(s).
Available Credit
- 1.25 AMA PRA Category 1 Credit™The Obesity Medicine Association (OMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Obesity Medicine Association designates this Live activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the commensurate amount with the extent of their participation in the activity.